Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intravenous immunoglobulin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    449 result(s) found for: Intravenous immunoglobulin. Displaying page 3 of 23.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-006560-11 Sponsor Protocol Number: FARM7J4HCH Start Date*: 2009-02-24
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Prevention of human cytomegalovirus (HCMV) mother-to-fetus transmission by administration of virus-specific hyperimmune globulin to pregnant women with primary HCMV infection
    Medical condition: Pregnant women with primary HCMV infection.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003608-61 Sponsor Protocol Number: ZLB06_002CR Start Date*: 2015-01-05
    Sponsor Name:CSL Behring
    Full Title: A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency
    Medical condition: Primary Immune Deficiency
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003459-12 Sponsor Protocol Number: RB-NAIT-01-01 Start Date*: 2020-08-11
    Sponsor Name:Rallybio, IPA, LLC
    Full Title: A Single-blind, Placebo-controlled, Single-center Study Investigating the Dose of Human Anti-Human Platelet Antigen (HPA)-1a Immune Globulin (NAITgam) Needed to Eliminate HPA-1a Positive Platelets ...
    Medical condition: prevention of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT In mothers negative for HPA-1a antigen, fetal platelets positive for HPA-1a antigen, may enter the mother’s circulation and induce pr...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10075151 Fetal and neonatal alloimmune thrombocytopenia LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001327-12 Sponsor Protocol Number: FIBHGM-ECNC001-2012 Start Date*: 2012-11-19
    Sponsor Name:Fundacion para la Investigación Biomédica del Hospital Gregorio Marañón
    Full Title: Assessing the efficacy and toxicity of intravenous immunoglobulin for the treatment of infections in patients with post solid organ transplantation IgG hypogammaglobulinemia
    Medical condition: infections in patients with post solid organ transplantation IgG hypogammaglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021428 - Immune system disorders 10054427 Hypogammaglobulinemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000256-35 Sponsor Protocol Number: CNPOBC2020 Start Date*: 2020-12-16
    Sponsor Name:Aalborg University Hospital
    Full Title: Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment: a randomised, double-blind, placebo-controlled trial
    Medical condition: Recurrent pregnancy loss after assisted reproductive technology treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10078356 Recurrent pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001710-37 Sponsor Protocol Number: NL73727 Start Date*: 2021-05-26
    Sponsor Name:Academisch Medisch Centrum
    Full Title: Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial.
    Medical condition: idiopathic inflammatory myopathies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001598-25 Sponsor Protocol Number: IG1002 Start Date*: 2011-10-25
    Sponsor Name:INSTITUTO GRIFOLS, S.A.
    Full Title: A multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmaphereses with infusion of human albumin combined with intra...
    Medical condition: Mild to Moderate Alzheimer's Disease patients.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004271-22 Sponsor Protocol Number: INSIGHTPROTOCOL006 Start Date*: 2015-02-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
    Medical condition: Infleunza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005015-82 Sponsor Protocol Number: NGAM-05 Start Date*: 2012-01-10
    Sponsor Name:Octapharma AG
    Full Title: Clinical study to evaluate the safety and tolerability of immunoglobulin intravenous (human) 10% (NewGam) administered at high infusion rates to patients with primary immunodeficiency diseases (ext...
    Medical condition: primary immunodeficiency diseases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10049485 Bruton's agammaglobulinemia LLT
    14.1 10021428 - Immune system disorders 10010112 Common variable immunodeficiency LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001696-32 Sponsor Protocol Number: GC2004 Start Date*: 2020-05-08
    Sponsor Name:Instituto Grifols, S.A
    Full Title: A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alo...
    Medical condition: Patients with Mild to Moderate Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000292-37 Sponsor Protocol Number: APHP200017 Start Date*: 2021-06-25
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Full Title: Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX).
    Medical condition: Adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001537-13 Sponsor Protocol Number: ALXN1210-NEPH-202 Start Date*: 2021-03-25
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Ne...
    Medical condition: Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005362-18 Sponsor Protocol Number: HBIGforcure Start Date*: 2022-04-13
    Sponsor Name:Hannover Medical School
    Full Title: Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B
    Medical condition: HBeAg negative patients with chronic HBV infection will be allocated into two different cohorts, cohort A and cohort B.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10052297 Hepatitis B e antigen negative PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005363-52 Sponsor Protocol Number: IOCtrial Start Date*: 2014-09-10
    Sponsor Name:Department of Neurology, Academic Medical Center
    Full Title: Intravenous immunoglobulin overtreatment in chronic inflammatory demyelinating polyneuropathy (CIDP)
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000417-33 Sponsor Protocol Number: VIB0551.P3.S2 Start Date*: 2020-09-30
    Sponsor Name:Viela Bio, Inc./Horizon Therapeutics Ireland DAC
    Full Title: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4 Related Disease
    Medical condition: Immunoglobulin G4-related disease (IgG4-RD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10077271 Immunoglobulin G4 related disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) HU (Completed) NL (Trial now transitioned) IT (Trial now transitioned) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000906-31 Sponsor Protocol Number: IgPro10_2001 Start Date*: 2020-05-22
    Sponsor Name:CSL Behring GmbH
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults with Sy...
    Medical condition: efficacy and safety in subjects with diffuse cutaneous systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) FR (Completed) PL (Prematurely Ended) BE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002090-21 Sponsor Protocol Number: IM103177 Start Date*: 2016-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression
    Medical condition: Maintenance of renal transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001663-24 Sponsor Protocol Number: INSIGHT012 Start Date*: 2021-09-20
    Sponsor Name:Office of Sponsored Projects,University of Minnesota
    Full Title: An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Out...
    Medical condition: We are investigating Coronavirus disease 2019 (COVID-19) which is predominantly a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004758-27 Sponsor Protocol Number: IVIGPANSOpen Start Date*: 2020-03-02
    Sponsor Name:Gillberg Neuropsychiatry Centre
    Full Title: Intravenous immunoglobulin (IVIG) treatment in children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS): an open-label trial in South-western Sweden
    Medical condition: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsions and...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004579-22 Sponsor Protocol Number: GAM-25 Start Date*: 2008-10-14
    Sponsor Name:Octapharma AG
    Full Title: A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam ...
    Medical condition: Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 13:14:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA